Selected research
Market Structure
Global Clotting Factors Ⅷ Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Clotting Factors Ⅷ market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Clotting Factors Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Clotting Factors Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Clotting Factors Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Clotting Factors Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Clotting Factors Ⅷ include Taibang Biological, Shanghai Laishi, Lvshizi and Hualan Biological, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Clotting Factors Ⅷ market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Clotting Factors Ⅷ and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Clotting Factors Ⅷ sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Clotting Factors Ⅷ market size, projected growth trends, production technologies, key applications, and end-use industries.
Clotting Factors Ⅷ Segment by Company
Taibang Biological
Shanghai Laishi
Lvshizi
Hualan Biological
Clotting Factors Ⅷ Segment by Type
Injection
Freeze-dried Injection
Clotting Factors Ⅷ Segment by Application
Hemophilia A
Bleeding Diseases
Clotting Factors Ⅷ Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Clotting Factors Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Clotting Factors Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Clotting Factors Ⅷ.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Clotting Factors Ⅷ market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Clotting Factors Ⅷ manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Clotting Factors Ⅷ in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Clotting Factors Ⅷ in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Freeze-dried Injection
Applications
- Hemophilia A
- Bleeding Diseases
Companies covered
- Taibang Biological
- Shanghai Laishi
- Lvshizi
- Hualan Biological
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Clotting Factors Ⅷ Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Clotting Factors Ⅷ Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Clotting Factors Ⅷ Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Clotting Factors Ⅷ Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Clotting Factors Ⅷ Market Dynamics
- 2.1 Clotting Factors Ⅷ Industry Trends
- 2.2 Clotting Factors Ⅷ Industry Drivers
- 2.3 Clotting Factors Ⅷ Industry Opportunities and Challenges
- 2.4 Clotting Factors Ⅷ Industry Restraints
3 Clotting Factors Ⅷ Market by Manufacturers
- 3.1 Global Clotting Factors Ⅷ Revenue by Manufacturers (2021-2026)
- 3.2 Global Clotting Factors Ⅷ Sales by Manufacturers (2021-2026)
- 3.3 Global Clotting Factors Ⅷ Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Clotting Factors Ⅷ Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Clotting Factors Ⅷ Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Clotting Factors Ⅷ Manufacturers, Product Type & Application
- 3.7 Global Clotting Factors Ⅷ Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Clotting Factors Ⅷ Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Clotting Factors Ⅷ Players Market Share by Revenue in 2025
- 3.8.3 2025 Clotting Factors Ⅷ Tier 1, Tier 2, and Tier 3
4 Clotting Factors Ⅷ Market by Type
- 4.1 Clotting Factors Ⅷ Type Introduction
- 4.1.1 Injection
- 4.1.2 Freeze-dried Injection
- 4.2 Global Clotting Factors Ⅷ Sales by Type
- 4.2.1 Global Clotting Factors Ⅷ Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Clotting Factors Ⅷ Sales by Type (2021-2032)
- 4.2.3 Global Clotting Factors Ⅷ Sales Market Share by Type (2021-2032)
- 4.3 Global Clotting Factors Ⅷ Revenue by Type
- 4.3.1 Global Clotting Factors Ⅷ Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Clotting Factors Ⅷ Revenue by Type (2021-2032)
- 4.3.3 Global Clotting Factors Ⅷ Revenue Market Share by Type (2021-2032)
5 Clotting Factors Ⅷ Market by Application
- 5.1 Clotting Factors Ⅷ Application Introduction
- 5.1.1 Hemophilia A
- 5.1.2 Bleeding Diseases
- 5.2 Global Clotting Factors Ⅷ Sales by Application
- 5.2.1 Global Clotting Factors Ⅷ Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Clotting Factors Ⅷ Sales by Application (2021-2032)
- 5.2.3 Global Clotting Factors Ⅷ Sales Market Share by Application (2021-2032)
- 5.3 Global Clotting Factors Ⅷ Revenue by Application
- 5.3.1 Global Clotting Factors Ⅷ Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Clotting Factors Ⅷ Revenue by Application (2021-2032)
- 5.3.3 Global Clotting Factors Ⅷ Revenue Market Share by Application (2021-2032)
6 Global Clotting Factors Ⅷ Sales by Region
- 6.1 Global Clotting Factors Ⅷ Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Clotting Factors Ⅷ Sales by Region (2021-2032)
- 6.2.1 Global Clotting Factors Ⅷ Sales by Region (2021-2026)
- 6.2.2 Global Clotting Factors Ⅷ Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Clotting Factors Ⅷ Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Clotting Factors Ⅷ Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Clotting Factors Ⅷ Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Clotting Factors Ⅷ Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Clotting Factors Ⅷ Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Clotting Factors Ⅷ Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Clotting Factors Ⅷ Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Clotting Factors Ⅷ Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Clotting Factors Ⅷ Revenue by Region
- 7.1 Global Clotting Factors Ⅷ Revenue by Region
- 7.1.1 Global Clotting Factors Ⅷ Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Clotting Factors Ⅷ Revenue by Region (2021-2026)
- 7.1.3 Global Clotting Factors Ⅷ Revenue by Region (2027-2032)
- 7.1.4 Global Clotting Factors Ⅷ Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Clotting Factors Ⅷ Revenue (2021-2032)
- 7.2.2 North America Clotting Factors Ⅷ Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Clotting Factors Ⅷ Revenue (2021-2032)
- 7.3.2 Europe Clotting Factors Ⅷ Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Clotting Factors Ⅷ Revenue (2021-2032)
- 7.4.2 Asia-Pacific Clotting Factors Ⅷ Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Clotting Factors Ⅷ Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Clotting Factors Ⅷ Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Taibang Biological
- 8.1.1 Taibang Biological Company Information
- 8.1.2 Taibang Biological Business Overview
- 8.1.3 Taibang Biological Clotting Factors Ⅷ Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Taibang Biological Clotting Factors Ⅷ Product Portfolio
- 8.1.5 Taibang Biological Recent Developments
- 8.2 Shanghai Laishi
- 8.2.1 Shanghai Laishi Company Information
- 8.2.2 Shanghai Laishi Business Overview
- 8.2.3 Shanghai Laishi Clotting Factors Ⅷ Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Shanghai Laishi Clotting Factors Ⅷ Product Portfolio
- 8.2.5 Shanghai Laishi Recent Developments
- 8.3 Lvshizi
- 8.3.1 Lvshizi Company Information
- 8.3.2 Lvshizi Business Overview
- 8.3.3 Lvshizi Clotting Factors Ⅷ Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Lvshizi Clotting Factors Ⅷ Product Portfolio
- 8.3.5 Lvshizi Recent Developments
- 8.4 Hualan Biological
- 8.4.1 Hualan Biological Company Information
- 8.4.2 Hualan Biological Business Overview
- 8.4.3 Hualan Biological Clotting Factors Ⅷ Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Hualan Biological Clotting Factors Ⅷ Product Portfolio
- 8.4.5 Hualan Biological Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Clotting Factors Ⅷ Value Chain Analysis
- 9.1.1 Clotting Factors Ⅷ Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Clotting Factors Ⅷ Production Mode & Process
- 9.2 Clotting Factors Ⅷ Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Clotting Factors Ⅷ Distributors
- 9.2.3 Clotting Factors Ⅷ Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst